Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Orkambi

- PMLiVE

Vertex shares positive late-stage results for triple combination cystic fibrosis treatment

The company compared the treatment to its current triple cystic fibrosis therapy

- PMLiVE

MHRA extends licence of Vertex’s cystic fibrosis drugs for young children

Kaftrio and Kalydeco are now approved for use in certain patients aged two to five years

- PMLiVE

Pioneering research collaboration seeks cure for cystic fibrosis

Backed by the non-profit Cystic Fibrosis Foundation and venture capital group Flagship, Pioneering Medicines will identify and develop genetic therapies for CF

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Amended agreement sees Vertex take control of gene therapy programme

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

- PMLiVE

Making a difference with patient support

A clear understanding of the patient journey and experience is pivotal in designing patient support programmes

Bedrock Healthcare Communications

- PMLiVE

CRISPR gene-editing in cancer patients is safe, according to new study

Patients had no side effects following CRISPR treatment

- PMLiVE

Vertex continues upward trajectory with French Orkambi deal

Comes on the heels of similar reimbursement deal in England

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links